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Sameer Imtiaz1,2* and Jürgen Rehm1,2,3,4,5,6Abstract
An influential study from the United States generated considerable discussion and debate. This study documented
rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century, with clear
linkages of all-cause mortality to increasing rates of poisonings, suicides and chronic liver disease deaths. All of
these causes of deaths are strongly related to the use of legal and illegal substances, but the study stressed the
importance of prescription opioids. Given the similarities between the United States and Canada in prescription
opioid use, the assessment of similar all-cause mortality trends is relevant for Canada. As this commentary
highlights, the all-cause mortality shifts seen in the United States cannot be seen in Canada for either sex or age
groups. The exact reasons for the differences between the two countries are not clear, but it is important for public
health to further explore this question.
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One of the most influential studies in public health in
the United States (US) in 2015 highlighted a reversal of
all-cause mortality decreases in midlife among white
non-Hispanic Americans in the 21st century [1]. This
study triggered numerous newspaper reports, as well
as debate [2–4]. It showed a clear link of all-cause
mortality in this group to increasing rates of poison-
ing, suicide and chronic liver disease deaths, all of
which are strongly related to use of legal and illegal
substances [5]. The non-medical use of prescription
opioids (POs) was especially stressed in the study as
the underlying risk factor for the all-cause mortality
increases [1]. Poisoning deaths related to POs, often
referred to as overdose deaths, have been strongly
linked to the overall level of PO use, with a near perfect
correlation of 0.99 [6].
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level of per capita use for the first time, Canada again
increased it. Moreover, non-medical use of POs is rela-
tively similar between the two countries. For example,
non-medical use of POs reached 7.7 % in 2010 for On-
tario [8], whereas the analogous estimate in the US was
5.5 % [9]. It should be noted, however, that non-
medical use of POs’ prevalence vary in both countries,
with variability strongly associated with exact phrasing
of relevant questions. Regarding other substance use,
alcohol consumption per capita is higher in Canada
than the US (10.2 L ethanol vs. 9.2 L ethanol) [10],
whereas past 12-month cocaine use is lower (1.3 % vs.
2.2 %) [11], as is lifetime heroin use (0.5 % vs. 1.8 %)
[12, 13]. Although the corresponding 12-month heroin
use estimate is not available for Canada, there is no rea-
son to believe that it would be higher than that ob-
served for the US.
Case and Deaton (2015) included Canada in their
comparisons with the US midlife age group (45–54
years), and found no such increase in all-cause mortality
for the midlife age group in Canada, but rather a
decrease. The present commentary extended similar
assessments to other age groups as well. Based on the
World Health Organization Mortality Database and
World Population Prospects Database [14, 15], all-le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 All-cause mortality rates for males from 1990–2011 in Canada
Year Deaths per 100,000
<15 Years 15–24 Years 25–34 Years 35–44 Years 45–54 Years 55–64 Years ≥65 Years
1990 81 103 124 190 447 1277 5412
2000 50 78 90 157 354 962 4937
Δ1990–2000 31 25 34 33 93 315 475
2000 50 78 90 157 354 962 4937
2011 48 61 74 123 296 752 3987
Δ2000–2011 2 17 17 34 58 211 950
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year age-groups. Changes in all-cause mortality rates
were thereafter calculated for each successive decade
from 1990 until 2011. Apart from changes in all-
cause mortality rates, Pearson’s product moment cor-
relations were computed between all-cause mortality
rates and drug poisoning mortality rates (ICD-10
X40-X44, X60-X64, X85 and Y10-Y14) by sex from
2000 to 2011. All mortality rates were standardized
according to the Canadian population in 1990.
The all-cause mortality rates for males decreased from
758 deaths per 100,000 in 1990 to 654 deaths per
100,000 in 2000 to 528 deaths per 100,000 in 2011,
indicating decreases of 104 deaths per 100,000
between 1990 and 2000 and 126 deaths per 100,000
between 2000 and 2011. The all-cause mortality rates
for females also decreased in the examined time
period, with decreases of 5 deaths per 100,000 (from
631 deaths per 100,000 to 626 deaths per 100,000)
and 64 deaths per 100,000 (from 626 deaths per
100,000 to 562 deaths per 100,000) between 1990 and
2000 and 2000 and 2011, respectively. The all-cause
mortality rates by age groups are presented in Table 1
for males and Table 2 for females. As evident by these
tables, all-cause mortality rates decreased between
1990, 2000 and 2011 for both sexes and all age
groups, with the exception of females 65 years and
older between 1990 and 2000.
The real decreases in all-cause mortality rates should
be higher, given that the average age within the ageTable 2 All-cause mortality rates for females from 1990–2011 in Can
Year Deaths per 100,000
<15 Years 15–24 Years 25–34 Years
1990 63 35 50
2000 39 34 41
Δ1990–2000 24 1 9
2000 39 34 41
2011 39 27 38
Δ2000–2011 0 7 3groups has been increasing (for the effect in the US see
[4]) [16]. This latter effect is likely also responsible for
the one exception in trends among the oldest females
during the first decade of observation.
The sex-specific all-cause mortality rates and drug poi-
soning mortality rates from 2000 to 2011 are displayed
in Fig. 1 (see Additional file 1: Tables S1 and S2 for the
data). Drug poisoning mortality rates increased for males
and females during the examined time period, despite
decreases in all-cause mortality rates for both sexes. As
a consequence, strong negative correlations were ob-
served between the two rates for males (r = −0.95, p <
0.01) and females (r = −0.91, p < 0.01). It follows that the
increases in drug poisoning mortality rates were not
large enough to drive up the all-cause mortality rates, as
was observed by Case and Deaton for the US [1].
It should also be noted that although the drug poison-
ing mortality rates increased between 2000 and 2011 in
Canada, these increases were considerably lower com-
pared with those observed in the US. For example, drug
poisoning mortality rates for those 45–54 years rose by
7 deaths per 100,000 and 6 deaths per 100,000 in
Canada for males and females, respectively. The analo-
gous increases in the US surmounted to 14 deaths per
100,000 for males and 16 deaths per 100,000 for females.
Given the similarities in the use of legal and illegal sub-
stances between the two countries, the observed differ-
ences in these trends are noteworthy, but the exact
reasons underlying these differences are not well
understood.ada
35–44 Years 45–54 Years 55–64 Years ≥65 Years
100 262 674 3880
91 229 573 3994
9 34 101 −115
91 229 573 3994
75 205 468 3623
17 23 105 371
Fig. 1 All-cause mortality rates (top panel) and drug poisoning mortality rates (bottom panel) by sex (2000–2011)
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In sum, the upward all-cause mortality shifts seen in the
US cannot be seen in Canada for either sex or age
groups, even though Canada has also been experiencing
increases in PO use, non-medical use of POs and related
overdose deaths [17, 18]. The exact reasons for the dif-
ferences between the two countries are not clear, but it
is important for public health to further explore this
question.
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